Prosecutors have sought arrest warrant for two executives of Kolon Life Science for submitting false data related to Invossa-K, the now-suspended osteoarthritis gene therapy.
The move came five months after the Ministry of Food and Drug Safety filed a complaint against the company for breaching the Pharmaceutical Affairs Act, signaling that the prosecution is close to wrapping up its investigation.
The Seoul Central District Prosecutors’ Office on Wednesday sought arrest warrants for the two Kolon executives, surnamed Kim and Cho, for the obstruction of justice by submitting fake data. The two allegedly submitted false documents related to the main ingredients of Invossa when applying for a sales license.
The food and drug safety ministry investigated earlier why the second fluid of Invossa contained a substance different from the one stated in the submitted document. The ministry concluded that Kolon Life Science intentionally hid the mislabeling of the ingredient to obtain approval for Invossa, and filed a complaint against Kolon on May 31. On July 9, the ministry revoked the license of Invossa.
Prosecutors started their probes by raiding the headquarters of Kolon Life Science and the Korean branch of Kolon TissueGene in June.
The prosecution is also looking at whether Kolon TissueGene violated the Capital Markets Act because it went public on the Kosdaq market in November 2017, after winning the license for Invossa.
<© Korea Biomedical Review, All rights reserved.>